SciBase Holding AB (SE:SCIB)
:SCIB
Want to see SE:SCIB full AI Analyst Report?
Top Page
SciBase Holding AB
(SCIB)
Select Model
Select Model
Rating:57Neutral
Price Target:
kr51.00
▲(15354.55% Upside)
Action:Reiterated
Date:06/09/26
The score is held back primarily by weak financial performance—large operating losses and significant cash burn despite improving revenue and solid gross margin. Technicals are a key offset, with strong trend support across major moving averages and positive momentum. Valuation is neutral-to-uncertain due to negative earnings (P/E not meaningful) and no dividend yield data.
Positive Factors
Revenue Growth
Steady multi-year revenue growth indicates expanding clinical adoption of the Nevisense platform and increasing test volumes. For a device-plus-consumables model this scaling creates a larger base of recurring usage-linked sales, improving prospects for operating leverage and long-term unit economics.
Negative Factors
Large Operating Losses
Very large negative operating and net margins show the cost base far exceeds current revenue, a structural issue rather than short-term variability. Persistent deep losses require continual funding, raise dilution risk, and mean profitability remains uncertain until revenue growth materially outpaces fixed and operating costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Steady multi-year revenue growth indicates expanding clinical adoption of the Nevisense platform and increasing test volumes. For a device-plus-consumables model this scaling creates a larger base of recurring usage-linked sales, improving prospects for operating leverage and long-term unit economics.
Read all positive factors
SciBase Holding AB (SCIB) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr499.51M
Dividend YieldN/A
Average Volume (3M)318.73K
Price to Earnings (P/E)―
Beta (1Y)-0.08
Revenue Growth41.17%
EPS Growth29.20%
CountrySE
Employees32
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-20.94
Shares Outstanding10,225,300
10 Day Avg. Volume218,776
30 Day Avg. Volume318,725
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)18.68
Price to Sales (P/S)3.07
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.33
Revenue Forecast (FY)kr69.80M
SciBase Holding AB Business Overview & Revenue Model
Company Description
SciBase Holding AB (publ), a medical technology firm founded in 1998 and headquartered in Sundbyberg, Sweden, specializes in the global development and distribution of instruments for diagnosing skin cancer and other dermatological issues. Their k...
How the Company Makes Money
SciBase primarily makes money by selling and supporting its diagnostic platform for skin assessment used in clinical settings. Revenue is generated from (1) system-related sales (the placement/sale of Nevisense devices to clinics and hospitals) an...
SciBase Holding AB Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 45.88M | 40.46M | 29.70M | 23.25M | 17.89M | 11.73M |
| Gross Profit | 26.91M | 27.10M | 21.08M | 16.04M | 11.23M | 6.58M |
| EBITDA | -76.00M | -81.49M | -57.59M | -51.83M | -39.33M | -38.58M |
| Net Income | -95.21M | -87.06M | -61.13M | -55.59M | -39.90M | -41.69M |
Balance Sheet | ||||||
| Total Assets | 103.69M | 52.17M | 61.73M | 64.33M | 49.85M | 85.46M |
| Cash, Cash Equivalents and Short-Term Investments | 71.25M | 22.60M | 11.24M | 34.12M | 18.83M | 65.61M |
| Total Debt | 23.93M | 23.03M | 4.18M | 6.80M | 8.12M | 2.86M |
| Total Liabilities | 45.58M | 45.51M | 25.08M | 21.28M | 24.62M | 14.66M |
| Stockholders Equity | 58.11M | 6.66M | 36.65M | 43.06M | 25.24M | 70.80M |
Cash Flow | ||||||
| Free Cash Flow | -85.38M | -84.81M | -57.81M | -52.37M | -44.85M | -40.12M |
| Operating Cash Flow | -85.15M | -84.58M | -57.38M | -51.98M | -44.47M | -39.50M |
| Investing Cash Flow | -228.00K | -228.00K | -428.00K | -383.00K | -381.00K | -526.00K |
| Financing Cash Flow | 122.74M | 96.29M | 34.91M | 67.68M | -2.48M | 64.22M |
SciBase Holding AB Technical Analysis
Positive
0.33
Price Trends
44.05
Positive
35.86
Positive
31.58
Positive
Market Momentum
1.54
Negative
58.33
Neutral
71.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SCIB, the sentiment is Positive. The current price of 0.33 is below the 20-day moving average (MA) of 47.61, below the 50-day MA of 44.05, and below the 200-day MA of 31.58, indicating a bullish trend. The MACD of 1.54 indicates Negative momentum. The RSI at 58.33 is Neutral, neither overbought nor oversold. The STOCH value of 71.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SCIB.
SciBase Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | kr124.48M | 36.17 | ― | ― | -12.51% | -59.88% | |
57 Neutral | kr499.51M | -4.21 | -253.54% | ― | 41.17% | 29.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr86.77M | -2.25 | ― | ― | -22.86% | 57.28% | |
46 Neutral | kr125.97M | -6.07 | ― | ― | ― | -4.00% | |
43 Neutral | kr105.03M | -3.25 | -61.62% | ― | -29.16% | 44.24% | |
43 Neutral | kr35.14M | -0.84 | -60.56% | ― | 27.31% | 6.31% |
* Healthcare Sector Average
SE:SCIB
SciBase Holding AB
48.90
17.82
57.32%
SE:CLS.B
Clinical Laserthermia Systems AB Class B
3.52
0.81
29.70%
SE:LXB
Luxbright AB
0.12
-0.59
-82.73%
SE:ARCOMA
Arcoma AB
9.60
0.06
0.63%
SE:NEOLA
Neola Medical AB
0.93
-1.20
-56.42%
SE:ICO
Iconovo AB
1.17
-0.53
-31.18%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.